Molecular Landscape in Ovarian Clear Cell Carcinoma

[1]  T. Kohno,et al.  Precision medicine for ovarian clear cell carcinoma based on gene alterations , 2020, International Journal of Clinical Oncology.

[2]  A. Kawabata,et al.  Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma , 2020, International Journal of Clinical Oncology.

[3]  R. Natrajan,et al.  Translational genomics of ovarian clear cell carcinoma. , 2019, Seminars in cancer biology.

[4]  Mariko Sasaki,et al.  Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. , 2019, Gynecologic oncology.

[5]  T. Fukumoto,et al.  HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. , 2019, Cancer research.

[6]  D. Provencher,et al.  Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  H. Tsuda,et al.  The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE) , 2019, International Journal of Gynecological Cancer.

[8]  Dale W. Garsed,et al.  Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype , 2019, Clinical Cancer Research.

[9]  K. Hasegawa,et al.  Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma , 2019, Scientific Reports.

[10]  Mariko Sasaki,et al.  Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. , 2019, Cancer cell.

[11]  K. Oda,et al.  Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. , 2018, Gynecologic oncology.

[12]  A. Tinker,et al.  A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium , 2018, Clinical Cancer Research.

[13]  D. Gershenson,et al.  Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). , 2018, Gynecologic oncology.

[14]  G. Mills,et al.  ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade , 2018, Nature Medicine.

[15]  Yi Kan Wang,et al.  Clear cell carcinomas of the ovary and kidney: clarity through genomics , 2018, The Journal of pathology.

[16]  J. Yasuda,et al.  Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing , 2018, Genes, chromosomes & cancer.

[17]  H. Chung,et al.  Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. , 2017, Gynecologic oncology.

[18]  Y. Okuno,et al.  Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. , 2017, The American journal of pathology.

[19]  A. Kawabata,et al.  Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma. , 2017, Gynecologic Oncology.

[20]  M. Stoler,et al.  Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium , 2017, Modern Pathology.

[21]  H. Watari,et al.  Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma , 2017, British Journal of Cancer.

[22]  Kathleen R. Cho,et al.  ARID1A-mutated ovarian cancers depend on HDAC6 activity , 2017, Nature Cell Biology.

[23]  Ali Bashashati,et al.  Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes , 2017, Nature Genetics.

[24]  J. Elvin,et al.  Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options , 2017, Gynecologic oncology reports.

[25]  Lauren L. Ritterhouse,et al.  Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression , 2017, Oncoimmunology.

[26]  A. Kawabata,et al.  Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference , 2017, Journal of gynecologic oncology.

[27]  Samuel E. Jones,et al.  ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A , 2016, Nature Communications.

[28]  A. Okamoto,et al.  Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  James T. Webber,et al.  Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib , 2016, Molecular Cancer Therapeutics.

[30]  N. Yanaihara,et al.  Antitumor effects of interleukin‐6 (IL‐6)/interleukin‐6 receptor (IL‐6R) signaling pathway inhibition in clear cell carcinoma of the ovary , 2016, Molecular carcinogenesis.

[31]  E. Oliva,et al.  Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 109 Cases , 2016, The American journal of surgical pathology.

[32]  S. Mabuchi,et al.  Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives , 2016, Journal of gynecologic oncology.

[33]  A. Iasonos,et al.  Ovarian clear cell carcinoma, outcomes by stage: the MSK experience. , 2015, Gynecologic oncology.

[34]  K. Yamaguchi,et al.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Wei Zhang,et al.  ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. , 2015, Cancer discovery.

[36]  H. Aburatani,et al.  Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas , 2015, PloS one.

[37]  N. Yanaihara,et al.  Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing. , 2015, International journal of oncology.

[38]  B. Monk,et al.  A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). , 2015, Gynecologic oncology.

[39]  Benjamin G. Bitler,et al.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.

[40]  N. Yanaihara,et al.  Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma , 2015, PloS one.

[41]  S. Murphy,et al.  Hepatocyte nuclear factor‐1β (HNF‐1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma , 2015, Molecular carcinogenesis.

[42]  Jeffrey S. Damrauer,et al.  Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signaling , 2014, Nature Communications.

[43]  H. Ahn,et al.  Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary. , 2014, Gynecologic oncology.

[44]  N. Yanaihara,et al.  Impact of Surgical Staging in Stage I Clear Cell Adenocarcinoma of the Ovary , 2014, International Journal of Gynecologic Cancer.

[45]  Y. Yatabe,et al.  Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates with Worsened Prognosis , 2013, PloS one.

[46]  N. Yanaihara,et al.  Cytokine gene expression signature in ovarian clear cell carcinoma. , 2012, International journal of oncology.

[47]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  N. Yanaihara,et al.  Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. , 2012, International journal of oncology.

[49]  Naveena Singh,et al.  Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.

[50]  A. Ashworth,et al.  Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas , 2011, Clinical Cancer Research.

[51]  Kylie L. Gorringe,et al.  IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer , 2011, Clinical Cancer Research.

[52]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[53]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[54]  R. Burger,et al.  Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary , 2010, Molecular Cancer Therapeutics.

[55]  S. Murphy,et al.  Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes , 2010, Oncogene.

[56]  I. Shih,et al.  DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma , 2010, Clinical Cancer Research.

[57]  J. Testa,et al.  mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary , 2009, Clinical Cancer Research.

[58]  Marketa Zvelebil,et al.  PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas , 2009, Clinical Cancer Research.

[59]  J. Chan,et al.  Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. , 2008, Gynecologic oncology.

[60]  J. Kigawa,et al.  Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging , 2006, British Journal of Cancer.

[61]  R. Broaddus,et al.  Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. , 2004, Human pathology.

[62]  N. Matsumura,et al.  Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival. , 2015, Oncotarget.